CAR T cell treatment for a specific brainstem glioma mutation
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 study tests a custom immune therapy called GD2 CAR T cells in children and adults with a specific type of diffuse midline glioma (DMG) that has the H3K27M mutation. The goal is to see if the treatment is safe and can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diffuse midline glioma (DMG) with an H3K27M (or H3K27I) mutation confirmed by a CLIA lab test
- Your age is between 2 and 60 years
- You finished radiation and prior chemotherapy/immunotherapy early enough (there are specific waiting periods between treatments)
- Your body systems are healthy enough (blood counts, liver/kidney tests, and heart/lung oxygen levels meet study cutoffs)
- You can meet the study visit schedule and, if needed, consent with a parent/guardian (or assent if a child)
- You can use birth control if you could become pregnant or make someone pregnant, starting now and for months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
This Phase 1 trial tests CAR T cells designed to attack a specific target (GD2) on a rare childhood brain/spinal tumor called DMG with a certain gene change (H3K27M). It is mainly designed to check safety and early signs of effectiveness after prior treatments.
This trial tests a special immune-cell therapy (GD2 CAR T cells) made for pediatric brain tumor patients. It uses a planned treatment plan and monitoring to see if the therapy is safe and can work against the tumor.
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
Hear when a new Glioma of Spinal Cord trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.